Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities: 2020-2023

Historic Other financing activities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2023 value amounting to $1.2 million.

  • Xeris Biopharma Holdings' Other financing activities rose 1875.00% to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year decrease of 65.11%. This contributed to the annual value of $1.2 million for FY2023, which is 75.70% down from last year.
  • As of FY2023, Xeris Biopharma Holdings' Other financing activities stood at $1.2 million, which was down 75.70% from $4.9 million recorded in FY2022.
  • Xeris Biopharma Holdings' Other financing activities' 5-year high stood at $5.6 million during FY2020, with a 5-year trough of $54,000 in FY2021.
  • For the 3-year period, Xeris Biopharma Holdings' Other financing activities averaged around $2.0 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Xeris Biopharma Holdings' Other financing activities crashed by 99.04% in 2021 and then spiked by 8,929.63% in 2022.
  • Yearly analysis of 4 years shows Xeris Biopharma Holdings' Other financing activities stood at $5.6 million in 2020, then tumbled by 99.04% to $54,000 in 2021, then skyrocketed by 8,929.63% to $4.9 million in 2022, then slumped by 75.70% to $1.2 million in 2023.